The 36-month beta value for SLN is at 1.39. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLN is 37.61M, and currently, shorts hold a 2.51% of that float. The average trading volume for SLN on July 10, 2025 was 184.60K shares.
SLN) stock’s latest price update
Silence Therapeutics Plc ADR (NASDAQ: SLN)’s stock price has gone rise by 9.64% in comparison to its previous close of $5.91, however, the company has experienced a 9.46% increase in its stock price over the last five trading days. businesswire.com reported 2025-06-12 that LONDON–(BUSINESS WIRE)—- $SLN #SenseofSilence–Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, Italy. “The latest data presented at EHA today continue to demonstrate divesiran’s potential to maintain rapid and dur.
SLN’s Market Performance
SLN’s stock has risen by 9.46% in the past week, with a monthly rise of 19.12% and a quarterly rise of 172.27%. The volatility ratio for the week is 7.74% while the volatility levels for the last 30 days are 8.56% for Silence Therapeutics Plc ADR The simple moving average for the past 20 days is 14.35% for SLN’s stock, with a -17.17% simple moving average for the past 200 days.
Analysts’ Opinion of SLN
Many brokerage firms have already submitted their reports for SLN stocks, with Goldman repeating the rating for SLN by listing it as a “Sell.” The predicted price for SLN in the upcoming period, according to Goldman is $6 based on the research report published on February 11, 2025 of the current year 2025.
Jefferies gave a rating of “Buy” to SLN, setting the target price at $40 in the report published on September 03rd of the previous year.
SLN Trading at 29.19% from the 50-Day Moving Average
After a stumble in the market that brought SLN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.16% of loss for the given period.
Stock Fundamentals for SLN
Current profitability levels for the company are sitting at:
- -2.76 for the present operating margin
- 0.73 for the gross margin
The net margin for Silence Therapeutics Plc ADR stands at -2.17. The total capital return value is set at -0.35. Equity return is now at value -99.23, with -43.26 for asset returns.
Based on Silence Therapeutics Plc ADR (SLN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 1153.24. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 26.22.
Currently, EBITDA for the company is -48.99 million with net debt to EBITDA at 1.09. When we switch over and look at the enterprise to sales, we see a ratio of 9.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.81.
Conclusion
In conclusion, Silence Therapeutics Plc ADR (SLN) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
